Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 4/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23156977 | 0.94 | KLK7 (0.51) | KLK7KLK5CTSKCTSSSYK | |
| SCHEMBL15083131 | 0.94 | KLK7 (0.51) | KLK7KLK5CTSKCTSSSYK | |
| SCHEMBL16288805 | 0.87 | PPARA (0.55) | KLK7KLK5CTSKCTSSSYK | |
| SCHEMBL5970500 | 0.87 | PPARA (0.52) | KLK7KLK5CTSKCTSSSYK | |
| SCHEMBL16574592 | 0.87 | KLK5 (0.57) | KLK7KLK5CTSKCTSSSYK | |
| SCHEMBL10284237 | 0.86 | CTSS (0.56) | KLK7KLK5CTSKCTSSSYK | |
| SCHEMBL14864738 | 0.86 | CTSS (0.56) | KLK7KLK5CTSKCTSSSYK | |
| SCHEMBL3817109 | 0.86 | PPARA (0.55) | KLK7KLK5CTSKCTSSSYK | |
| SCHEMBL1517760 | 0.86 | PPARA (0.55) | KLK7KLK5CTSKCTSSSYK | |
| SCHEMBL8322873 | 0.85 | KLK5 (0.53) | KLK7KLK5CTSKCTSSSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | KLK7 326/4885KLK5 403/4885CTSK 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.